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In a short hairpin RNA screen for genes that affect AKT phosphorylation, we identified the RAB35 small guanosine triphosphatase (GTPase)-a protein previously implicated in endomembrane trafficking-as a regulator of the phosphatidylinositol 3′-OH kinase (PI3K) pathway. Depletion of RAB35 suppresses AKT phosphorylation in response to growth factors, whereas expression of a dominant active GTPase-deficient mutant of RAB35 constitutively activates the PI3K/AKT pathway. RAB35 functions downstream of growth factor receptors and upstream of PDK1 and mTORC2 and copurifies with PI3K in immunoprecipitation assays. Two somatic RAB35 mutations found in human tumors generate alleles that constitutively activate PI3K/AKT signaling, suppress apoptosis, and transform cells in a PI3K-dependent manner. Furthermore, oncogenic RAB35 is sufficient to drive platelet-derived growth factor receptor a to LAMP2-positive endomembranes in the absence of ligand, suggesting that there may be latent oncogenic potential in dysregulated endomembrane trafficking. and lipid or protein kinases. Because AKT phosphorylation is a faithful indicator of PI3K activity, we used an immunofluorescent approach to quantitatively measure phosphorylation of AKT at serine 473 (S473) (4) in HeLa cells, which display robust growth factor-induced AKT phosphorylation and lack mutations in core PI3K signaling pathway genes (Fig. 1A) . We screened a collection of 7450 shRNAs in an arrayed format in triplicate to identify kinases or guanosine triphosphatases (GTPases) whose depletion could alter PI3K-dependent AKT phosphorylation.
To identify shRNAs that altered AKT phosphorylation (i.e., "hits"), we translated the phospho-AKT signal in each screened well to a z score (5) . shRNAs targeting genes that positively regulate AKT phosphorylation (pAKT)-RICTOR, PIK3CA, PIK3CB, AKT1, and AKT3-all diminished AKT phosphorylation and scored as "pAKT-low" hits ( Fig. 1B and tables S1 to S3). Conversely, shRNAs targeting genes whose protein products inhibit AKT signaling-such as RAPTOR and RHEBelevated phospho-AKT levels and scored as "pAKT-high" hits. Thus, our screen successfully identified known regulators of PI3K/AKT signaling, as well as a number of genes not previously implicated in regulation of the pathway (table S4). We prioritized hits for genes that had no reported link to PI3K/AKT signaling (table S5) and searched oncogenomic databases to identify those with somatic mutations reported in human cancers (6, 7) . This left us with a list of 29 genes (table S6), 26 of which were pAKT-low hits. Next, we grouped the 26 pAKT-low hits by their annotated functions from the literature and found that the bestrepresented functional group was the RAB GTPases, which are well known to regulate intracellular protein trafficking (Fig. 1C) . This finding suggests that dysregulated protein trafficking by mutant RAB proteins could play a role in oncogenesis.
Of the five RAB proteins that appeared in our list in table S6 (see also Fig. 1C ), we pursued RAB35 because, in addition to meeting all of the criteria mentioned previously, it is a well-studied GTPase for which reagents and tools are readily available. RAB35 is a regulator of cytoskeletal organization and trafficking at the recycling endosome (8) (9) (10) (11) . Endomembrane trafficking by RAB35 is regulated by the DENND1 family of RAB35 guanine nucleotide exchange factors (9, (12) (13) (14) and by the TBC1D10 family of RAB35 GTPase activating proteins (15) (16) (17) . Because RAB35 was and an anti-phospho-S473 AKT monoclonal antibody (green) (top). Signals were imaged and quantified with a near-infrared scanner, and the phospho-AKT signal intensity was divided by the whole-cell stain signal intensity to calculate a normalized phospho-AKTvalue for each well (bottom). (B) Averaged (n = 3 replicates) phospho-AKT z scores of screened shRNAs. HeLa cells were plated in 384-well plates, transduced with lentiviral reagents expressing control shRNAs or shRNAs targeting human kinases and GTPases, and then processed as in (A). Phospho-AKT z scores for each shRNA were calculated, averaged, and arranged as indicated. (C) Functional grouping of the 26 genes whose knockdown lowered AKTphosphorylation, that are not known to regulate PI3K/AKTsignaling, and that are mutated in human cancers. Numbers indicate the number of genes in each functional group. MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; cAMP, adenosine 3′,5′-monophosphate. (D) Representation of somatic mutations in RAB35 in cancer found in oncogenomic databases. Mutations predicted by the cBioPortal for Cancer Genomics to have a medium effect on protein function are noted in black, whereas mutations predicted to have a high effect are noted in red. Table S7 contains a full list of somatic mutations of RAB35 found in cancers. aa, amino acids. (E) shRNAs targeting RAB35 deplete RAB35 protein levels and inhibit AKTphosphorylation. HeLa cells were transduced with lentiviruses expressing the indicated shRNAs, starved overnight and treated with serum as indicated, and lysed; cell lysates were analyzed by immunoblotting. Red asterisks indicate shRNA "hits" from our screen. FBS, fetal bovine serum.
a robust hit in our screen ( fig. S1A ), has not been implicated as a regulator of PI3K/AKT signaling, and has somatic mutations that have been reported in human cancers mapping to residues conserved in other small GTPases ( Fig. 1D and table S7), we prioritized RAB35 for further study.
Next, we confirmed that depletion of RAB35 with the same shRNAs that scored in the original screen suppressed AKT phosphorylation to a similar extent as depletion of the mTORC2 component RICTOR (Fig. 1E) . Furthermore, additional shRAB35 hairpins not present in the original screen also suppressed AKT phosphorylation, as well as the AKT substrate FOXO1/3A (fig. S1B). Thus, multiple independent shRNAs targeting RAB35 consistently impair AKT phosphorylation in HeLa cells.
To ensure that the effect of RAB35 knockdown on AKT signaling was not cell-type specific, we depleted RAB35 protein in human embryonic kidney (HEK) 293 E cells and in murine NIH-3T3 cells (Fig. 2, A and B) . Knockdowns of RAB35 with two different shRNAs diminished AKT phosphorylation at S473 in response to serum stimulation in both human and mouse cells and did so more potently than RICTOR. Furthermore, the PI3K-dependent phosphorylation of FOXO1/3A and the SGK1 substrate NDRG-1 was also decreased in cells depleted of RAB35. We expanded this analysis to seven additional cancer cell lines with different mutational backgrounds (oncogenic PI3KCA or KRAS, deleted PTEN, mutated NF2 or TP53) and generally found reduced AKT phosphorylation after RAB35 depletion, with some modest differences that are likely attributable to distinct hairpins in distinct cellular contexts ( fig. S2, A to C) . Furthermore, AKT phosphorylation at the PDK1 phosphorylation site T308 was consistently reduced by RAB35 knockdown, suggesting that RAB35 may function upstream of PDK1. Collectively, these data indicate that RAB35 is broadly necessary for the efficient activation of PI3K/AKT signaling in response to serum stimulation.
To explore whether RAB35 is sufficient to activate the PI3K/AKT pathway, we generated cell (Fig. 2C and fig. S3 ). However, expression of the active RAB35 Q67L mutant rendered AKT phosphorylation (at both T308 and S473) constitutively elevated and refractory to growth factor deprivation but did not affect ERK phosphorylation. FOXO1/3A phosphorylation was also consistently elevated in serumdeprived cells expressing RAB35
Q67L
. Therefore, the expression of GTP-bound RAB35 is sufficient to activate PI3K/AKT signaling in cells, even in the absence of growth factors.
The fact that RAB35 Q67L results in constitutive phosphorylation of T308 as well as S473 suggests that RAB35 may function upstream of the SCIENCE sciencemag.org T308 kinase PDK1 (18, 19) . However, attribution of RAB35 function to PDK1 versus mTORC2 activation is challenging because the phosphorylation states of T308 and S473 are interdependent (20) (21) (22) . To address this issue, we took advantage of cells that stably express alleles of murine AKT1 (mAkt1) in which either T308 or S473 were mutated to phosphomimetic aspartate residues (23) (fig. S4, A and B) . As expected, mTOR blockade with the TORC1/2 inhibitor torin1 or blockade by RICTOR depletion (resulting in loss of mTORC2 function) suppressed phosphorylation at both sites in mAkt1 wt -expressing cells ( fig. S4C ). In mAkt1
S473D
-expressing cells, which lack a regulated mTORC2 site, these same interventions either had no effect on T308 phosphorylation (RICTOR depletion) or enhanced T308 phosphorylation (torin 1).
Having confirmed the ability of this system to distinguish direct effects on T308 versus S473, we examined the impact of RAB35 knockdown. Unlike depletion of RICTOR or treatment with fig. S4C ). These data suggest that RAB35 signals to AKT by functioning upstream of both PDK1 and mTORC2.
We reasoned that if RAB35 acts upstream of both PDK1 and mTORC2, it may be controlling their common regulator, PI3K. Although we could not detect an interaction between endogenous RAB35 and PI3K, we found that stably expressed RAB35, but not RHEB, copurified with PI3K when the kinase was immunoprecipitated by its p85 subunit (Fig. 2D) . Interestingly, more FLAG-tagged RAB35 (FLAG-RAB35) copurified with PI3K in immunoprecipitates from cells expressing constitutively GTP-bound RAB35 Q67L than from cells expressing RAB35 wt . Conversely, we found that the same experiment performed using lysates from cells stably expressing a constitutively guanosine diphosphate-bound allele of RAB35 (RAB35 S22N ) did not recover any FLAG-RAB35. Thus, the physical association of RAB35 and PI3K is nucleotide-dependent. We also asked whether RAB35 is necessary for PI3K kinase activity in vitro. As expected, PI3K immunopurified from cells depleted of PI3Ka had significantly reduced in vitro kinase activity toward phosphatidylinositol 4,5-bisphosphate ( fig.  S5A ) . PI3K purified from cells depleted of RAB35 had a~50% reduction in PI3K kinase activity in vitro. Further, we found that depletion of RAB35 did not reduce the amount of p110a recovered in p85 immunoprecipitates, which suggests that RAB35 depletion does not disrupt the p85-p110a interaction ( fig. S5B) . Thus, RAB35 copurifies with PI3K in a nucleotide-dependent manner and may be required for optimal PI3K enzymatic function.
Given that RAB35 functions upstream of PI3K, we investigated whether RAB35 acts downstream of any particular growth factor receptor. Depletion of RICTOR, PI3Ka, or RAB35 in HeLa cells reduced S473 phosphorylation of AKT in response to treatment with either insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), platelet-derived growth factor AA (PDGF-AA), or vascular endothelial growth factor (VEGF) ( fig.  S6A ). RAB35 depletion did not dramatically alter phosphorylation of ERK or tyrosine phosphorylation of receptors for IGF, EGF, PDGF, or VEGF (IGFR, EGFR, PDGFR, or VEGFR, respectively) ( fig. S6, B and C) . Collectively, these data suggest a model in which RAB35 functions upstream of PI3K and downstream of growth factor RTKs to activate AKT. One criterion for prioritization of genes on our hit list (table S6) was evidence for mutation in human cancer databases (table S7) . For RAB35, missense mutations have been reported at two residues that are conserved in RAS-like GTPases, A151T and F161L. We noticed that the A151T and F161L mutations in RAB35 were markedly similar to two well-documented KRAS mutations (A146T and F156L) that have been previously identified in human tumor samples (Fig. 3A ) (24, 25) . Although they are not canonical activating mutations, stable expression of either of these two KRAS mutants was sufficient to activate ERK signaling and transform NIH-3T3 cells in vitro. We therefore asked whether the two similar mutations in RAB35 might also be gain-offunction mutations that activate RAB35 signaling.
To test this possibility, we generated NIH-3T3 cells stably expressing either RAB35 wt , GTPasedeficient RAB35 Q67L , or the RAB35 A151T and RAB35 F161L alleles reported in human tumors. As expected from our earlier experiments in human cells, expression of RAB35 wt did not activate AKT phosphorylation upon serum deprivation, whereas expression of the GTPase-deficient RAB35 Q67L did (Fig. 3B) . Notably, expression of the two naturally occurring RAB35
A151T and RAB35 F161L mutants also elevated AKT phosphorylation levels during serum deprivation, indicating that both are gain-of-function alleles sufficient to activate PI3K/AKT signaling.
Because PI3K/AKT signaling inhibits apoptosis, we next examined whether cells expressing mutant RAB35 alleles are resistant to apoptosis triggered by growth factor withdrawal. 
expressing RAB35
wt were sufficient to elevate cleaved levels of the apoptotic markers PARP and caspase 3 (Fig. 3C) . In comparison, cells stably expressing one of the three RAB35 mutants or oncogenic p110a H1047R had decreased levels of cleaved PARP and cleaved caspase 3 after serum withdrawal. Further, although cells expressing RAB35 wt died in response to serum deprivation, cells expressing mutant alleles of RAB35 or p110a
H1047R had significantly improved cell viability when deprived of growth factors (Fig. 3D) . Taken together, these data suggest that mutant RAB35 proteins can mitigate cell death in response to growth factor deprivation.
To determine whether the mutant alleles of RAB35 are oncogenic, we examined their activity in a standard NIH-3T3 cell focus-formation assayan in vitro model of density-independent growth that often correlates with tumorigenicity (26) . NIH-3T3 cells expressing oncogenic p110a H1047R , myristoylated AKT1 (AKT1 myr ), or any of the three mutant alleles of RAB35, but not RAB35 wt , formed foci ( Fig. 3E and fig. S7 ). Moreover, we found that when cultured in medium containing 250 nM of the pan-class I PI3K inhibitor GDC-0941 (27) , cells expressing RAB35 mutants and p110a
H1047R were unable to form foci. Not surprisingly, PI3K blockade did not inhibit the growth of cells transduced with AKT1 myr . Thus, the expression of the RAB35 mutants identified in human cancers can transform NIH-3T3 cells in vitro in a PI3K-dependent manner.
Because RAB proteins regulate endomembrane trafficking, we considered whether our evidence implicating RAB35 in AKT activation, downstream of RTKs and upstream of PI3K, is linked to this more established function of RAB proteins. The fact that many RTKs undergo ligand-stimulated internalization and recycling through endosomes, while remaining competent to signal (28) (29) (30) (31) (32) , suggests that RAB35 may function in this process. In considering this possibility, we noted highly elevated levels of tyrosine phosphorylation of the PDGFRa/b-but not of IGF1R, fibroblast growth factor receptor, VEGFR, or MET-in cells expressing the constitutively active RAB35 Q67L allele (Fig. 4A and fig. S8 ). This increase in PDGFRa/b phosphorylation was markedly reduced by treatment of cells with crenolanib (CP-868596), a PDGFR inhibitor that affects both PDGFRa and PDGFRb with similar potency (33) (34) (35) (Fig. 4B  and fig. S9 ). Notably, crenolanib treatment also diminished phosphorylation of AKT and the downstream substrate FOXO1/3A, suggesting that the RAB35 Q67L allele activates AKT through PDGFR. Treatment with a more b-selective PDGFR inhibitor (CP-673451) only moderately affected AKT phosphorylation, implicating PDGFRa as the most likely RAB35 Q67L target. The pan-PI3K inhibitor (GDC-0941) and the PI3Ka-specific inhibitor (BYL719) both suppressed AKT phosphorylation but not PDGFRa/b phosphorylation, providing further evidence that PDGFR/RAB35 Q67L functions upstream of PI3K.
We postulated that RAB35 Q67L might initiate PDGFR-mediated AKT activation by altering PDGFRa localization. To explore this possibility, we transfected cells that stably expressed either RAB35 wt or RAB35 Q67L with cDNA encoding for myc-tagged PDGFRa and studied the localization of tagged PDGFRa in the presence or absence of the PDGFRa ligand PDGF-AA ( fig. S10) (Fig. 4, C and D, and fig. S12 ) and EEA1 ( fig. S13 ). We also found that FLAG-RAB35 is present in endomembranes that contain LAMP2 ( fig. S14A ) but not in those that contain EEA1 ( fig. S14B ). This suggests that PI3K activity downstream of RAB35 Q67L may originate on LAMP2-positive membranes. Finally, because it has been established that PI3K activity is required for the internalization and trafficking of PDGFRs (36, 37), we asked whether the localization of PDGFRamyc in cells expressing RAB35 Q67L was a result of the increased PI3K signaling in these cells. Although PI3K was required for ligand-induced PDGFRa internalization in cells that express RAB35 wt ( fig. S15A) , treatment of cells expressing RAB35
Q67L with a pan-PI3K inhibitor did not diminish the localization of PDGFRa-myc to LAMP2-positive compartments ( fig. S15B ). PI3K inhibitor treatment resulted in changes in LAMP2 vesicle morphology that may merit further investigation ( fig. S15, A and B) . Together, these data establish that activated PDGFRa is normally trafficked through LAMP2-positive endomembranes and that constitutively active RAB35 likely drives unliganded PDGFRa to this location, where it is active and can signal to PI3K/AKT (Fig. 4E) . Further study is required to determine whether mutant RAB35 diverts newly synthesized PDGFRa from the cell membrane to LAMP2-positive endomembranes or prevents the exit of existing PDGFRa from LAMP2 compartments.
Here we demonstrate a previously unappreciated role for the small GTPase RAB35 in regulating growth factor signaling to PI3K/AKT. We also characterize two RAB35 missense mutations found in human tumors that confer gain of function in standard transformation assays, displaying phenotypes similar to well-characterized oncogenic KRAS alleles. Searches of existing human tumor sequencing databases reveal that RAB35 mutations are rare (table S7) and are therefore unlikely to appear on current lists of human cancer genes that rely solely on statistical methods to distinguish between driver and passenger mutations. Nonetheless, the conserved location of the RAB35 mutations to analogous residues in KRAS and their oncogenic phenotype in functional assays provide strong evidence that these are true driver mutations and are perhaps clinically actionable on the basis of their sensitivity to PI3K inhibition. Considering the broad role of RAB family proteins in endomembrane trafficking, it is intriguing to speculate that the oncogenic RAB35 phenotype reported here may be a consequence of dysregulated membrane trafficking. Our studies showing that the constitutively active RAB35 Q67L allele is sufficient to drive PDGFRa to LAMP2-positive endomembranes, in a pattern that mirrors that seen with native PDGF-AA ligand, are consistent with this model. Alternatively, these mutations may be neomorphic, conferring a novel molecular function to RAB35 that results in signaling in a RAS-like manner. The fact that other RAB proteins (RAB1B, RAB39, RABL3, RASEF) emerged as hits in our screen and have rare missense mutations reported in human tumors (table S6) begs a broader examination of this question.
